No significant increase in hazard ratios seen for GI events for semaglutide versus dulaglutide, tirzepatide versus dulaglutide, tirzepatide versus semaglutide. (HealthDay News) — For patients with ...

Please provide your email address to receive an email when new articles are posted on . Dulaglutide, semaglutide and tirzepatide had similar GI safety profiles. An increased risk for GI adverse events ...

HOUSTON — The dual GLP-1/GIP receptor agonist tirzepatide showed significantly greater efficacy than the GLP-1 dulaglutide in the treatment of major kidney outcomes in patients with type 2 diabetes ...

A prespecified analysis of the SURPASS CVOT trial examining patients with high-risk CKD suggested tirzepatide reduces the risk of major kidney events, particularly eGFR decline and albuminuria, ...

A large cohort study found three popular GLP-1-based diabetes drugs -- semaglutide, dulaglutide, and tirzepatide -- carry similar risks for serious adverse GI events, with a rate of about 12 per 1,000 ...

Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of ...

I’ve worn a middle parting since I was a teenager. Never a side part. On very rare occasions, I’ve ever-so-slightly tilted it to one side, as a tentative way of switching it up. Legendary French ...

The three GLP-1 receptor agonist (RA) drugs liraglutide (Victoza), semaglutide (Ozempic), and dulaglutide (Trulicity) provided similar cardiovascular and kidney benefits in people with type 2 diabetes ...

Risks for kidney failure and major cardiovascular events between three GLP-1 receptor agonists were similar among veterans with diabetes. Mortality risk and certain adverse events differed between the ...

About The Study: In this comparative effectiveness study in veterans with diabetes, liraglutide, semaglutide, and dulaglutide initiators had similar risks for kidney and cardiovascular outcomes.